Product Information
DABIGATRAN ETEXILATE 150 MG CP is a generic product labeled by Apotex Corp., priced at $0.8569 per EA under NDC 60505434806. Its NADAC has been published 117 times since Apr 3, 2024.
Strength
150 mg/1
Manufacturer
Apotex Corp.NDC
60505434806
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208070On Market Since
2/13/2024
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 150 MG CP has been published 117 times since Apr 3, 2024, and over the history we have for it it has declined 69.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8569 per EA |
|---|---|
| All-time high | $2.8528 (Jul 10, 2024) |
| All-time low | $0.8446 (Feb 18, 2026) |
| 52-week high | $1.4231 |
| 52-week low | $0.8446 |
| Median price | $1.5822 |
| Average price | $1.5754 |
| Largest weekly change | +47.0% (Jun 19, 2024) |
| Weeks tracked | 117 |
| Tracking since | Apr 3, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the dabigatran etexilate market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 150 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 150 MG CP, manufactured by Apotex Corp., is $0.8569 per EA (NDC 60505434806), effective Jun 24, 2026.
How has the price of DABIGATRAN ETEXILATE 150 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has declined 69.6%. It has been tracked across 117 weekly CMS publications since Apr 3, 2024.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 150 MG CP?
Since Apr 3, 2024, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has ranged from a low of $0.8446 (Feb 18, 2026) to a high of $2.8528 (Jul 10, 2024), with a median of $1.5822 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 150 MG CP?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of DABIGATRAN ETEXILATE 150 MG CP, so no direct lower-cost alternative is listed.
Who manufactures DABIGATRAN ETEXILATE 150 MG CP?
DABIGATRAN ETEXILATE 150 MG CP (NDC 60505434806) is labeled by Apotex Corp., and CMS classifies it as a generic product.
Related Drugs
Same classification